Vectura Group plc Global development agreement with Dynavax (0976O)
16 August 2017 - 4:00PM
UK Regulatory
TIDMVEC
RNS Number : 0976O
Vectura Group plc
16 August 2017
Vectura Group plc
Global development agreement with Dynavax for lung cancer
programme using Vectura's smart nebuliser technology (VR347)
Chippenham, UK - 16 August 2017: Vectura Group plc (LSE: VEC)
("Vectura", "the Group"), an industry-leading device and
formulation business for inhaled airways products, today announces
that following successful completion of the feasibility work it has
signed an exclusive global agreement with Dynavax Technologies
Corporation (NASDAQ: DVAX; "Dynavax"), a clinical-stage
immunotherapy company, for the clinical application of Vectura's
proprietary smart nebuliser technology to deliver Dynavax's
investigational immunotherapeutic agent to lung cancer patients
(VR347).
VR347
Vectura's AKITA(R) smart nebuliser will be used by Dynavax to
deliver DV281, a novel Toll-Like Receptor 9 (TLR9) agonist designed
specifically for local delivery to primary lung tumours and lung
metastases in order to generate an anti-tumour immune response.
Vectura's FAVORITE(TM) nebulisation technology combines optimising
patient's inhalation technique with the effective control of the
flow rate and volume of the drug being delivered. This approach
maximises the efficiency of the nebulisation and enables consistent
targeted drug deposition.
The AKITA(R) device will initially be used in the development
programme with a plan to move to the FOX(R) handheld device as a
next step.
The agreement covers the Phase I and Phase II development
programmes and Vectura will provide devices and device related
support to Dynavax which is responsible for the rest of the
programme. Whilst addressing a substantial market opportunity, in
these early phases the Group is eligible to receive modest
milestones and development services revenues and does not expect a
material impact on R&D expenditure which remains within the
previous annual guidance range of GBP65-75m for 2017 and 2018.
James Ward-Lilley, Chief Executive Officer, commented:
"We are pleased to announce this additional new programme
leveraging Vectura's smart nebulisation device technology. The
collaboration with Dynavax is an exciting innovative programme
combining the development of a new treatment option for patients
with lung cancer along with targeted inhaled delivery. This
agreement underlines the increasing recognition of the utility of
Vectura's unique smart nebuliser technology and devices by existing
and potential development partners."
- ENDS -
For more enquiries, please contact
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading device and formulation business
for inhaled airways products offering a uniquely integrated inhaled
drug delivery platform. With our extensive range of device and
formulation technologies, integrated capabilities and
collaborations, we are a leader in the development of inhalation
products, increasing our ability to help patients suffering from
respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer,
Chiesi, Almirall, Janssen, and Tianjin KingYork. For further
information, please visit Vectura's website at www.vectura.com.
About DV281
DV281 is Dynavax's proprietary investigational TLR9 agonist
designed specifically for focused delivery to primary lung tumors
and lung metastases. DV281 is similar in biological activity and
mechanism of action to Dynavax's Phase II immunotherapy candidate,
SD-101, but has been optimised for administration as an aerosol.
Both SD-101 and DV281 activate plasmacytoid dendritic cells which
then stimulate T cells specific for antigens released from dying
tumor cells. TLR9 agonists such as DV281 and SD-101 have been shown
to stimulate potent Type 1 interferon induction along with
maturation of dendritic cells to effective antigen-presenting
cells, both activities are important for the induction of effective
anti-tumor immunity.
About Dynavax
Dynavax is a clinical-stage immunology company focused on
leveraging the power of the body's innate and adaptive immune
responses through toll-like receptor (TLR) stimulation. Dynavax is
developing product candidates for use in multiple cancer
indications and as a vaccine for the prevention of hepatitis B.
Dynavax's lead product candidates are SD-101, an investigational
cancer immunotherapeutic currently in Phase II studies, HEPLISAV-B,
a Phase III investigational adult hepatitis B vaccine, and DV281,
planned to enter the clinic in 2017. For more information, please
visit www.dynavax.com.
Forward-looking statements
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Vectura's
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
02:15 PM - 02:45 PM
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRGGUQGRUPMPPA
(END) Dow Jones Newswires
August 16, 2017 02:00 ET (06:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024